Sep 22, 2023
Dr. Schetelig on the Use of Induction Chemotherapy Prior to Allo-HCT in Relapsed/Refractory AML
Johannes Schetelig, MD, MSc, head, Stem Cell Transplantation Unit, University Hospital TU Dresden, head, DKMS Clinical Trials Unit, discusses whether patients with active relapsed/refractory acute myeloid...
Quelle: onclive.com